Description
Betamethasone valerate (BMV) is a synthetic glucocorticoid that is commonly used to treat psoriasis and dermatitis. BMV exhibits immunomodulatory, anti-inflammatory, and vasoconstrictive activity in vitro and in vivo. Across animal models of varying ages, BMV impairs maturation and viability of Langerhans and epidermal cells. BMV also decreases endogenous phospholipase activity and inhibits vasodilatory responses in skin; this partial vasoconstriction decreases blood flow, often resulting in a decrease in local TGF-β1 levels.
References
Naldi L, Yawalkar N, Kaszuba A, et al. Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. Am J Clin Dermatol. 2011 Jun 1;12(3):191-201. PMID: 21284407.
Meindl S, Vaculik C, Meingassner JG, et al. Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and mice. J Invest Dermatol. 2009 Sep;129(9):2184-92. PMID: 19295616.
Leivo T, Arjomaa P, Oivula J, et al. Differential modulation of transforming growth factor-beta by betamethasone-17- valerate and isotretinoin: corticosteroid decreases and isotretinoin increases the level of transforming growth factor-beta in suction blister fluid. Skin Pharmacol Appl Skin Physiol. 2000 May-Aug;13(3-4):150-6. PMID: 10859533.
Marks R, Sawyer M. Glucocorticoid-induced vasoconstriction in human skin. An inhibitory role on phospholipase A2 activity. Arch Dermatol. 1986 Aug;122(8):881-3. PMID: 2874773.
